<P>&nbsp;</P> <P><STRONG><STRONG><A style="COLOR: #e02020" title="" href="https://www.aderly.com/centre-recherche-et/developpement-france,p,21,EN.jsp" target=_blank>The Lyon-Gerland site, one of the most important science parks in Europe dedicated to life sciences and innovative technologies</A></STRONG>, continues to be solicited for large-scale biotechnology projects</STRONG>. This area, which contains 30 public research laboratories and 2000 businesses, is the epicenter of the global competitive cluster for research on infectious diseases.</P> <P>&nbsp;</P> <P><STRONG>During the <A style="COLOR: #e02020" title="" href="https://www.aderly.com/lyon-economic-news/New_Medical_technologies-news-L-ADERLY%2C-UN-PARTENAIRE-DE-LA-BIOVISION-INVESTOR-CONFERENCE,n,7021,EN.jsp" target=_blank>BioVision trade fair, the World Forum for Life Sciences</A>, which took place at the end of March 2013</STRONG>, G&#233;rard Collomb made a number of suggestions, including the idea of transferring the International Agency for Research on Cancer (IARC) to Gerland.</P> <P>&nbsp;</P> <P>Another large-scale project is the <STRONG>extension of the Jean Merieux bio-safety level 4 laboratory</STRONG>, with 200 additional square meters by the end of 2012, in order to include a biological resource center. Even more ambitious in nature is <STRONG><STRONG><A style="COLOR: #e02020" title="" href="https://www.aderly.com/lyon-economic-news/biotechnologie-france-europe-news-AGUETTANT-INVESTIT-DANS-SON-SITE-DE-PRODUCTION-LYONNAIS-,n,6710,EN.jsp" target=_blank>Aguettant&#8217;s project to extend the Gerland 2 laboratory by over 10,000 sq.m</A></STRONG>, thereby creating the space to house the company headquarters, factory, laboratory, and a research and development center</STRONG>. In total almost 300 employees will move to the premises by 2015.</P> <P>&nbsp;</P> <P><STRONG><STRONG><A style="COLOR: #e02020" title="" href="https://www.aderly.com/france-biotechnologies-biotech/entreprise-lyon-genzyme-biotechnologies-biotech,p,122,EN.jsp" target=_blank>Genzyme, a subsidiary of Sanofi</A></STRONG>, will also accommodate on its site a new state of the art platform</STRONG> dedicated to manufacturing products for the company Transgene. Sanofi, world leader in vaccines, and Merial, which specializes in veterinary medicines and vaccines, will group together their activities on a single site in 2016, in order to &#8220;harmonize and create more synergy&#8221;, announced Olivier Charmeil, CEO of Sanofi Pasteur, during a press conference. <BR></P> <P align=justify>.<BR></P>